uric acid has been researched along with Central Nervous System Diseases in 21 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
Central Nervous System Diseases: Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord.
| Excerpt | Relevance | Reference |
|---|---|---|
| ": A multicenter study with randomized, placebo-controlled, double-blind, parallel-group comparison was carried out to evaluate the efficacy and safety of febuxostat in 103 patients with hyperuricemia (including patients with gout) in Japan." | 9.15 | Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study. ( Fujimori, S; Hada, T; Hisashi, Y; Hosoya, T; Kamatani, N; Kenjiro, K; Kohri, K; Matsuzawa, Y; Nakamura, T; Naoyuki, K; Shin, F; Takanori, U; Tatsuo, H; Tetsuya, Y; Toshikazu, H; Toshitaka, N; Ueda, T; Yamamoto, T; Yamanaka, H; Yuji, M, 2011) |
| ": A multicenter study with randomized, placebo-controlled, double-blind, parallel-group comparison was carried out to evaluate the efficacy and safety of febuxostat in 103 patients with hyperuricemia (including patients with gout) in Japan." | 5.15 | Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study. ( Fujimori, S; Hada, T; Hisashi, Y; Hosoya, T; Kamatani, N; Kenjiro, K; Kohri, K; Matsuzawa, Y; Nakamura, T; Naoyuki, K; Shin, F; Takanori, U; Tatsuo, H; Tetsuya, Y; Toshikazu, H; Toshitaka, N; Ueda, T; Yamamoto, T; Yamanaka, H; Yuji, M, 2011) |
| "In multiple sclerosis, myelopathy, stroke, epilepsy and viral meningitis glutamate, hypoxanthine, xanthine, and uric acid are increased 2-3-fold compared to controls." | 1.30 | Cerebrospinal fluid hypoxanthine, xanthine and uric acid levels may reflect glutamate-mediated excitotoxicity in different neurological diseases. ( Kempski, OS; Lowitzsch, K; Stover, JF, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (52.38) | 18.7374 |
| 1990's | 5 (23.81) | 18.2507 |
| 2000's | 2 (9.52) | 29.6817 |
| 2010's | 3 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sloane, JA | 1 |
| Blitz, D | 1 |
| Margolin, Z | 1 |
| Vartanian, T | 1 |
| Kamatani, N | 1 |
| Naoyuki, K | 1 |
| Fujimori, S | 1 |
| Shin, F | 1 |
| Hada, T | 1 |
| Toshikazu, H | 1 |
| Hosoya, T | 1 |
| Tatsuo, H | 1 |
| Kohri, K | 1 |
| Kenjiro, K | 1 |
| Nakamura, T | 1 |
| Toshitaka, N | 1 |
| Ueda, T | 1 |
| Takanori, U | 1 |
| Yamamoto, T | 1 |
| Tetsuya, Y | 1 |
| Yamanaka, H | 1 |
| Hisashi, Y | 1 |
| Matsuzawa, Y | 1 |
| Yuji, M | 1 |
| Bollée, G | 1 |
| Dahan, K | 1 |
| Flamant, M | 1 |
| Morinière, V | 1 |
| Pawtowski, A | 1 |
| Heidet, L | 1 |
| Lacombe, D | 1 |
| Devuyst, O | 1 |
| Pirson, Y | 1 |
| Antignac, C | 1 |
| Knebelmann, B | 1 |
| Kastenbauer, S | 2 |
| Pfister, H- | 1 |
| LESCH, M | 1 |
| NYHAN, WL | 2 |
| Becker, BF | 1 |
| Ködel, U | 1 |
| Kiesl, D | 1 |
| Pfister, HW | 1 |
| Sumi, S | 1 |
| Wada, Y | 2 |
| Revuelta, M | 1 |
| Romero-Ramos, M | 1 |
| Venero, JL | 1 |
| Millan, F | 1 |
| Machado, A | 1 |
| Cano, J | 1 |
| Stover, JF | 1 |
| Lowitzsch, K | 1 |
| Kempski, OS | 1 |
| Sugita, K | 1 |
| Hagisawa, S | 1 |
| Satoh, Y | 1 |
| Eguchi, M | 1 |
| Furukawa, T | 1 |
| Swaroop, AK | 1 |
| Bedi, HK | 1 |
| Khalsa, N | 1 |
| Sharma, PK | 1 |
| Saito, T | 1 |
| Rundle, AT | 1 |
| Fannin, CV | 1 |
| Kekre, S | 1 |
| Singh, SD | 1 |
| Chhaparwal, BC | 1 |
| Pohowalla, JN | 1 |
| Sonntag, RW | 1 |
| Lampkin, B | 1 |
| McWilliams, NB | 1 |
| Mauer, AM | 1 |
| Nissen, NI | 1 |
| Dano, K | 1 |
| Storti, E | 1 |
| Quaglino, D | 1 |
| Berman, PH | 1 |
| Balis, ME | 1 |
| Dancis, J | 1 |
| Arakawa, T | 1 |
| Koizumi, K | 1 |
5 reviews available for uric acid and Central Nervous System Diseases
| Article | Year |
|---|---|
A clear and present danger: endogenous ligands of Toll-like receptors.
Topics: Apoptosis; Central Nervous System; Central Nervous System Diseases; Extracellular Matrix; Heat-Shock | 2010 |
[Xanthine oxidase deficiency (hereditary xanthinuria), molybdenum cofactor deficiency].
Topics: Central Nervous System Diseases; Coenzymes; Diagnosis, Differential; Diet Therapy; Humans; Infant, N | 1996 |
Uric acid studies in serum and cerebrospinal fluid in neurological disorders with mental retardation.
Topics: Carbohydrate Metabolism, Inborn Errors; Central Nervous System Diseases; Cerebral Palsy; Child; Chil | 1971 |
Treatment of acute leukemia.
Topics: Asparaginase; Bacterial Infections; Central Nervous System Diseases; Child; Child, Preschool; Cyclop | 1972 |
[New principles of treatment in acute leukemia].
Topics: Adolescent; Adult; Antineoplastic Agents; Central Nervous System Diseases; Child; Cyclophosphamide; | 1970 |
1 trial available for uric acid and Central Nervous System Diseases
| Article | Year |
|---|---|
Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
Topics: Adult; Central Nervous System Diseases; Dental Enamel; Diabetes Mellitus, Type 2; Dose-Response Rela | 2011 |
15 other studies available for uric acid and Central Nervous System Diseases
| Article | Year |
|---|---|
Phenotype and outcome in hereditary tubulointerstitial nephritis secondary to UMOD mutations.
Topics: Adult; Belgium; Biomarkers; Central Nervous System Diseases; Chi-Square Distribution; Dental Enamel; | 2011 |
Protection against meningitis-associated central nervous system complications by uric acid.
Topics: Central Nervous System Diseases; Humans; Meningitis, Bacterial; Models, Neurological; Uric Acid | 2002 |
A FAMILIAL DISORDER OF URIC ACID METABOLISM AND CENTRAL NERVOUS SYSTEM FUNCTION.
Topics: Athetosis; Biomedical Research; Blood Chemical Analysis; Central Nervous System Diseases; Cerebral P | 1964 |
Urate oxidation in CSF and blood of patients with inflammatory disorders of the nervous system.
Topics: Allantoin; Blood-Brain Barrier; Brain; Central Nervous System Diseases; Guillain-Barre Syndrome; Hum | 2004 |
Less induced 1-methyl-4-phenylpyridinium ion neurotoxicity on striatal slices from guinea-pigs fed with a vitamin C-deficient diet.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Amino Acids; Animals; Ascorbic Acid Def | 1997 |
Cerebrospinal fluid hypoxanthine, xanthine and uric acid levels may reflect glutamate-mediated excitotoxicity in different neurological diseases.
Topics: Adult; Albumins; Central Nervous System Diseases; Cerebrovascular Disorders; Chromatography, High Pr | 1997 |
Recurrent hepatosplenomegaly and peripheral blood cytopenia, persistent Epstein-Barr virus infection and central nervous system manifestation in a patient with lymphadenopathy and low serum uric acid.
Topics: Central Nervous System Diseases; Child, Preschool; Hepatomegaly; Herpesviridae Infections; Herpesvir | 1998 |
Uric acid levels in neurological and psychiatric disorders.
Topics: Adult; Central Nervous System Diseases; Female; Humans; Male; Middle Aged; Psychotic Disorders; Uric | 1976 |
[Clinical aspects of hyponatremia].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Central Nervous System Diseases; Child; Child, Preschool | 1991 |
A survey of serum uric acid levels in mentally retarded patients.
Topics: Adolescent; Adult; Aged; Athetosis; Central Nervous System Diseases; Down Syndrome; Female; Humans; | 1966 |
[General medical measures in neoplastic diseases and their complications].
Topics: Anemia; Central Nervous System Diseases; Humans; Hypercalcemia; Hyperinsulinism; Hyperparathyroidism | 1967 |
Dysmetabolic and neurological complications in leukemia patients treated with L-asparaginase.
Topics: Asparaginase; Central Nervous System Diseases; Child; Clinical Enzyme Tests; Drug Hypersensitivity; | 1970 |
Diagnostic test for congenital hyperuricemia with central nervous system dysfunction.
Topics: Carbon Isotopes; Central Nervous System Diseases; Erythrocytes; Glucosyltransferases; Humans; Hypoxa | 1968 |
Lesch-Nyhan syndrome: autopsy findings and in vitro study of incorporation of 14C-8-inosine into uric acid, guanosine-monophosphate and adenosine-monophosphate in the liver.
Topics: Adrenal Glands; Brain; Carbon Isotopes; Central Nervous System Diseases; Cerebellum; Humans; In Vitr | 1968 |
A disorder of uric acid metabolism and cerebral function in childhood.
Topics: Central Nervous System Diseases; Child; Child, Preschool; Fingers; Humans; Infant; Intellectual Disa | 1965 |